177 Helminths, Bedbugs, Scabies, and Lice Infections
• Immigration and travel continue to increase the parasitic diseases seen in emergency departments.
• Consider parasitic infections in patients presenting with abdominal pain, diarrhea, unexplained fever, rash, or eosinophilia.
• History of illness, travel, occupation, recreation, and behavior is paramount in diagnosing parasitic disease.
Helminths
Perspective
Parasite morbidity includes anemia, growth stunting, undernutrition, disfigurement, reduced work capacity, and increased susceptibility to other infections. Complications can include elephantiasis, blindness, gastroenterologic and urinary obstruction, and bladder cancer. Despite the widespread distribution of helminthic disease, research funding comprises less than 1% of global dollars spent.1
Nemathelminthes (Roundworms)
Intestinal Roundworms: Ascaris
Epidemiology
Ascariasis infects approximately 25% of the world’s population.1,2 It is prevalent in warm countries and areas of poor sanitation and is endemic to the southern United States. Ova can remain infective for several years. They are sensitive to temperatures higher than 65° C or lower than 20° C, direct sunlight, and organic solvents. Ascaris lumbricoides reaches up to 40 cm and is characterized by a constricted area at the junction of the first and middle thirds. The golden brown ovoid eggs measure 60 by 40 mcm.
Intestinal Roundworms: Necator and Ancylostoma (Hookworms)
Epidemiology
Hookworm infestations of Ancylostoma duodenale prevail in southern Europe, northern Asia, and North Africa, whereas Necator americanus is the main species affecting the Western Hemisphere and equatorial Africa. Worldwide, 1 billion persons are believed to be infected with hookworms.3 The frequency of infection is a general indication of the local level of hygiene and sanitation. Disease burden from hookworms results in iron-deficiency anemia and hypoproteinemia.
Intestinal Roundworms: Strongyloides
Epidemiology
Strongyloides stercoralis is found in the tropics, subtropics, and in temperate areas, and it affects an estimated 55 million to 100 million persons.4 Strongyloides is endemic to Southeast Asia, Latin America, the West Indies, Bangladesh, Pakistan, Africa, Spain, and the Appalachian region of the United States. S. stercoralis is an unusual helminth in its ability to replicate within the human host, thus resulting in continuous autoinfection. The infection is often difficult to eradicate, especially in immunocompromised hosts (Box 177.1). The larvae can disseminate and can cause systematic disease and mortality.
Box 177.1 Strongyloidiasis in the Immunocompromised Patient
Immunocompromised hosts are at risk for hyperinfection syndromes, in which filariform larvae cause colitis, malabsorption, ulcerative enteritis, ileus, systemic dissemination, gram-negative sepsis, meningitis, pneumonia, intraabdominal abscess, or acute respiratory distress syndrome. Immunosuppressive therapy, especially glucocorticoids, should be avoided in patients suspected to have Strongyloides infection because hyperinfection and iatrogenically caused fatal outcomes may result. Additional risk factors for hyperinfection and disseminated strongyloidiasis include infection with human T-cell lymphotropic virus-1, solid organ transplantation, hematologic malignant disease, hypogammaglobulinemia, uremia, malnutrition, diabetes mellitus, and chronic alcohol consumption.4 Strongyloides does not appear to be a common opportunistic pathogen in human immunodeficiency virus (HIV)–positive patients, and the risk of hyperinfection is not increased with HIV coinfection.4
Presenting Signs and Symptoms
Patients may be asymptomatic or have mild abdominal discomfort, cough, dyspnea, wheezing, and peripheral eosinophilia. Ten percent of patients present with wheezing as their primary complaint.5 If adult worms invade the duodenojejunal mucosa, the symptoms can mimic those of peptic ulcer disease, and small bowel obstruction may occur.
Diagnosis and Medical Decision Making
Stool examinations need to be repeated 3 to 5 times. An immunosorbent assay for aspiration or biopsy of duodenojejunal contents is also available. Serum immunoglobulin G (IgG) antibodies can be detected with enzyme-linked immunosorbent assay (ELISA). In disseminated strongyloidiasis, sputum, bronchoalveolar lavage samples, and surgical drainage fluids should be examined for larvae. Eosinophilia greater than 5% or a finding of more than 400 eosinophils/microliter is consistent with Strongyloides infection.5
Intestinal Roundworms: Enterobius (Pinworms)
Tissue Nematodes: Trichinella
Tissue Nematodes: Filaria
Epidemiology
Filarial nematodes are estimated to infect 170 million persons.1 Four main species cause most serious infections: Wucheria bancrofti, Brugia malayi, Onchocerca volvulus, and Loa loa. W. bancrofti is found in Africa, South America, Asia, the Pacific islands, and the Caribbean. Brugia species are found mainly in Southeast Asia, Asia, and Indonesia.
Treatment
Wolbachia bacterial endosymbionts are present in most filarial worms, with the exception of L. loa. When patients are treated with diethylcarbamazine, a hypersensitivity reaction to the intracellular Wolbachia may occur and may progress to encephalopathy. Diehtylcarbamazine should not be used as treatment, except for Loa loa, because the hypersensitivity reaction can lead to hypotension or angioedema. Chemotherapy and vaccine development directed against Wolbachia are under investigation.6
Platyhelminthes (Flatworms)
Cestode: Taenia Solium (Pork Tapeworm)
Epidemiology
Taenia has a worldwide distribution and is highly endemic in Latin America, Africa, Eastern Europe, Central and South Asia, and the Middle East.7 Approximately 45 Taenia species and subspecies are currently recognized.8 T. solium infection of the CNS, or neurocysticercosis, is a leading cause of acquired epilepsy and may result in more than 50,000 deaths annually.9
Presenting Signs and Symptoms
Severe signs and symptoms may include intestinal obstruction, appendicitis, and perforation. The worms occasionally migrate to the biliary system, respiratory tract, uterine cavity, or nasopharynx. If cysts are in the CNS, the patient may present with seizures, meningitis, stroke, or signs of increased intracranial pressure. Approximately 30% of patients with neurocysticercosis have residual calcification, and less than 20% have seizures.7 Parasite invasion of the ventricles can result in obstructive hydrocephalus. Extraparenchymal disease leads to a worse prognosis, secondary to invasive cyst growth and increased cerebrospinal fluid (CSF) debris and inflammation.7 Classic calcified lesions from prior infections are often seen on computed tomography (CT) or magnetic resonance imaging (MRI).
Treatment
Calcified cysts do not warrant antiparasitic therapy.10 Patients with seizures may be treated with antiepileptics, and occasionally endoscopic surgery or ventriculoperitoneal shunting is necessary to relieve obstructive hydrocephalus. Corticosteroids may help mitigate cerebrovascular complications and may be used in the treatment of cysticercotic encephalitis.
Cestode: Echinococcus
Epidemiology
Echinococcosis is caused by the larval invasion of Echinococcus granulosus, Echinococcus multilocularis, and Echinococcus vogeli. These cestodes are ubiquitous, with particularly heavy endemicity in Central Asia, the Mediterranean, the Middle East, South America, and eastern Africa. E. multilocularis is confined to the Northern Hemisphere. E. granulosus causes cystic echinococcosis, with 3 million cases, and E. multilocularis is responsible for the alveolar variant, with half a million cases.11 Canines are the definitive hosts and pass echinococcal eggs in feces. Intermediate mammalian hosts then ingest the eggs, and eventually cysts develop. The cycle is continued as canines eat infected meat.
Cestode: Diphyllobothrium (Fish Tapeworm)
Epidemiology
Diphyllobothrium species are estimated to infect more than 20 million people. Although an overall decline in North America, Europe, and Asia has been reported, outbreaks have occurred in Russia, Japan, South Korea, Italy, France, Switzerland, and South America.12 Diphyllobothrium also enjoys a range of hosts, from humans to foxes, bears, sea birds, and other fish-eating mammals.
Transmission and Life Cycle
Crustaceans, usually Cyclops or Diaptomus species, ingest the free-swimming embryos, known as coracidia. The coracidia penetrate the crustacean intestinal wall and develop into a procercoid. The crustacean host is eaten by a freshwater or marine fish, and additional development takes place. The procercoid larva migrates into fish tissue and organs and sometimes encysts. Multiple predatory fish, such as perch, pike, burbot, walleye, snook, Alaska blackfish, salmon, whitefish, trout, and Japanese anchovy have been implicated as hosts.12 After the host ingests a meal of undercooked or raw fish, Diphyllobothrium matures in the human gastrointestinal tract within a few weeks.
Trematoda: Schistosoma
Epidemiology
Human schistosomiasis, also known as bilharziasis, remains a serious health threat in Africa, Southeast Asia, South America, and the Middle East.1 Schistosomiasis is a complex of acute and chronic parasitic infections caused by digenetic blood nematodes. Infections with Schistosoma haematobium (bladder fluke), Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, and Schistosoma intercalatum (intestinal flukes) cause illness in humans. Schistosomes have been documented to infect humans for thousands of years and are associated with agricultural civilizations of the great river valleys. Hematuria, most likely caused by S. haematobium, occurred in ancient Egypt and Mesopotamia.13
Signs and Symptoms
Patients may be asymptomatic initially, or they may show mild pruritic maculopapular skin lesions within hours to days after exposure to cercariae. Four to 8 weeks after invasion, some patients may present with fever, eosinophilia, lymphadenopathy, and hepatosplenomegaly. Acute schistosomiasis or Katayama fever resembles serum sickness, and it appears to be related to antigen excess during sexual maturation of the parasite. It is associated with a mortality rate of up to 25%.13
Eggs induce an immune response as they travel to the liver, intestine, bladder, and rarely, to the brain or spinal cord. Granuloma formation in the bowel wall with S. mansoni or S. japonicum may cause bloody diarrhea, cramping, and colonic polyposis. Schistosoma can also cause pulmonary and CNS disease, with sequelae including pulmonary hypertension, cor pulmonale, epilepsy, and transverse myelitis.13
Egg retention and granuloma formation in the urinary tract with S. haematobium can lead to hematuria, urinary tract infections, glomerulonephritis, obstructive uropathy, dysuria, and bladder polyps and ulcerations. S. haematobium is considered a carcinogen in squamous cell bladder cancer.13
Treatment
Helminths cause a large burden of disease, yet their coevolution with humans and adaptation to our immune defenses may be beneficial (Box 177.2). Numerous epidemiologic and experimental studies have noted the low prevalence of allergy and autoimmune disease among populations with chronic helminth infections. Helminth infections generally cause a skewed type 1 helper T-cell (Th2) response. The Th1 arm of the immune system is often suppressed or downregulated. Populations with chronic helminthiases may not clear microbial infections adequately or respond optimally to vaccination.14,15 Schistosoma and Onchocerca infections appear to decrease tetanus and tuberculosis vaccine efficacy, and Ascaris infection similarly dampens the immune response to Mycoplasma pneumonia vaccination.16
Box 177.2 Helminth Immunomodulation
“The hygiene hypothesis suggests that microbes and worms are important for shaping and tuning the development and function of our immune system.”18
As developed countries experience better sanitation and reduced exposure to infectious disease agents, the immune system may be left “uneducated” and may develops “incorrect” or uncontrolled inflammation responses: rhinitis, atopic dermatitis, asthma, inflammatory bowel disease, multiple sclerosis, and type 1 diabetes mellitus.17 Helminth infections as therapies have been observed to decrease colitis in both murine and human models. A few studies have shown benefit from Trichuris infection in patients with inflammatory bowel disease; similar results have been reported in patients with multiple sclerosis.14,16–18 Much more research is needed to characterize human-helminth immunomodulatory dynamics. Genetics and environment play important roles.
Bedbugs
Epidemiology
Bedbugs, or cimicids, are insects that have plagued humankind since ancient Egypt.19 These ectoparasites are found in temperate and tropical regions worldwide, and global infestations are increasing. Much media attention has been paid to bedbugs, and millions of dollars have been spent in the hospitality and private sectors. Travelers, backpackers, immigrants, guest workers, the homeless, and persons sharing close quarters, such as military barracks and dormitories, are potential hosts and vectors.
Transmission and Life Cycle
Cimicids are wingless, obligate hematophages. Both sexes require blood meals. Cimex lectularius and Cimex hemipterus are the two species that prefer human hosts. Adults are oval, flat, approximately 5 mm in length, and reddish brown. Adults can survive for up to 12 months, perhaps even 2 years, without feeding.20 Nymphs tend to be lighter in color. Bedbugs usually conceal themselves during the day, often in bedding, carpet, wallpaper, or any crevice, usually within 1 to 2 m of a host.
Presenting Signs and Symptoms
Anaphylaxis and asthma have also been reported, and they may be related to increased exposure with subsequent feedings.21 Saliva of bedbugs contains a protein, nitrophorin, that may be responsible for cutaneous reactions.21 Beyond the physical irritation, bedbugs are responsible for anxiety, stigma, and insomnia.
Treatment
Topical antipruritics such as paroxime, doxepin, or corticosteroids may alleviate dermal irritation. Oral antibiotics may be necessary if lesions become secondarily infected by skin flora. For anaphylactic and urticarial reactions, supportive therapy including epinephrine, antihistamines, and corticosteroids is warranted. Much speculation remains about bedbugs as vectors for multiple diseases. Although human immunodeficiency virus (HIV) can be detected in bedbugs after a concentrated blood meal days later, no viral replication has been found, nor has virus been detected in the feces. Similarly, hepatitis B virus antigen has also been detected weeks after a feeding, but no internal replication has been observed.21 Concern about insecticide resistance is widespread.21,22
Scabies
Epidemiology
Scabies is a common parasitic infection caused by the mite Sarcoptes scabiei var. hominis, an arthropod of the order Acarina. Worldwide prevalence is estimated at 300 million.23 Scabies is endemic in sub-Saharan Africa, South and Central America, India, the South Pacific, and among Aboriginal communities in Australia. Additionally, infestations are sporadic in industrial countries. Overcrowding, poor hygiene and poor nutrition, poverty, war, and dementia are predisposing factors. Despite the stigma of scabies as an infection of the poor, scabies affects all ethnic and socioeconomic groups.
Signs and Symptoms
Crusted, or Norwegian, scabies is usually confined to immunocompromised, older, cognitively impaired, and institutionalized patients. Presumably, the lack of scratching may allow superinfection to occur.24 Crusted scabies represents a hyperinfection with thousands to millions of mites present. The lesions appear hyperkeratotic, similar to psoriatic papules, and can cover large areas of the scalp, face, neck, and extremities. Skin crusts may be loose or adherent, flaky or thick. Nail involvement is common with crusted scabies, as are eczematization and impetigo. Large flakes of epidermis slough off, carrying mites and furthering transmission. In crusted scabies, high levels of IgE and IgG and peripheral eosinophilia are present.24
Nodular scabies manifests with pruritic, violaceous nodules localized to the groin, axilla, and male genitalia. These nodules may represent a variant hypersensitivity reaction because mites are not found within them. Rarely, bullous lesions may occur with scabies, perhaps because of superinfection with Staphylococcus. Pyodermas, or bacterial skin infections, may be secondary to scabies infections, especially in the tropics.25
Treatment
Patient Teaching Tips
Scabies is a benign, easily treated disease commonly called “the itch.”
It causes a pruritic rash and spreads rapidly among people in close proximity.
Transmission among family members and within institutional settings is common.
Itching can persist for up to 4 to 6 weeks after the completion of treatment.
Schools do not ordinarily provide the level of contact necessary for transmission.
Head Lice
Epidemiology
Lice are epidemic throughout the world. Pediculus humanus species are permanent ectoparasites that require multiple blood meals a day. Infections are becoming more difficult to treat because of increasing resistance to common pediculicides. Lice prevalence is estimated at 6 to 12 million cases annually in the United States alone and more than 1 million globally.26–28
Transmission and Pathophysiology
Pediculus species carry out their entire life cycle on the human host and survive only briefly in the environment. One female head louse can lay up to 150 eggs during her 1-month life span. Eggs (nits) are cemented onto hair shafts of the host and hatch in 1 week; full maturation to adult stages is completed in another week. If nits are found less than 1 cm from the scalp, an active infestation is considered highly likely. Because human hair grows at a rate of 1 cm/month, and nits can remain attached to hair for up to 6 months, the presence of nits a few centimeters from the scalp may not represent an active infestation.26 Lice are transferred directly from host to host. Eggs are transferred from louse-infested clothing or personal articles such as shared combs, headphones, beds, and hats. Head lice can live up to 55 hours without a host.
Treatment
Three main avenues exist for treatment: mechanical removal, topical agents, and oral therapy (Table 177.1). Children can return to school immediately after completion of the first application of a topical insecticide. Wet hair combing to remove P. humanus capitis nits and adults is not as effective as the use of topical agents. Infested clothing and bed linen should be washed in hot water, dry cleaned, or discarded.
ORGANISM | TREATMENT | PRECAUTIONS AND COMMENTS |
---|---|---|
Roundworms: Intestinal | ||
Ascaris | Albendazole 400 mg PO × 1 Mebendazole 500 mg PO × 1 Mebendazole 100 mg PO bid × 3 days Pyrantel pamoate 11 mg/kg × 1 |
Maximum dose, 1 g |
Ivermectin 150-200 mcg/kg PO × 1 | Lactating/pregnant women Weight > 15 kg |
|
Necator, Ancylostoma | Albendazole 400 mg PO × 1 Mebendazole 500 mg PO × 1 or 100 mg PO bid × 3 days Pyrantel pamoate 11 mg/kg PO × 3 days Supplemental iron PO |
Maximum dose, 1 g |
Strongyloides: simple | Ivermectin 200 mcg/kg PO × 2 days; ± repeat in 1-2 wk | Lactating/pregnant women Weight > 15 kg |
Albendazole 400 mg PO bid × 3-7 days; ± repeat in 1-2 wk | ||
Strongyloides: disseminated | Ivermectin 200 mcg/kg PO once daily; continue +2 wk after symptom resolution + Albendazole or thiabendazole |
Lactating/pregnant women Weight > 15 kg |
Albendazole 400 mg PO bid; continue +2 wk after symptom resolution Thiabendazole 25 mg/kg PO bid; continue +2 wk after symptom resolution |
||
Enterobius | Albendazole 400 mg PO × 1 Mebendazole 100 mg PO × 1 Pyrantel pamoate 11 mg/kg PO × 1 |
Maximum dose, 1 g TOC for pregnant women |
Trichuris | Albendazole 400 mg PO × 3 days Mebendazole 200 mg PO × 3 days Ivermectin 200 mcg/kg PO × 3 days |
Lactating/pregnant women Weight > 15 kg |
Roundworms: Tissue | ||
Trichinella: mild | Supportive therapy | |
Trichinella: hypersensitivity | Corticosteroid taper | |
Trichinella: enteric only | Albendazole 15 mg/kg/day PO × 10-15 days, may repeat in 5 days Mebendazole 5 mg/kg/day PO × 10-15 days, may repeat in 5 days Corticosteroids if severe disease |
|
Cutaneous larva migrans | Albendazole 400-800 mg/day PO × 3-5 days Ivermectin 200 mcg/kg PO × 2 days |
|
Lymphatic filariasis Wucheria bancrofti Brugia malayi |
Diethylcarbamazine 6 mg/kg/day PO × 12 days Albendazole 400 mg PO bid × 21-30 days Doxycycline 200 mg PO once daily × 8 wk |
Hypersensitivity reaction |
Albendazole 400 mg PO × 1 + diethylcarbamazine 6 mg/kg PO × 1 or Ivermectin 200-400 mcg/kg PO × 1 |
Microfilariacidal only Lactating/pregnant women Weight > 15 kg |
|
Loa loa | Diethylcarbamazine 8-10 mg/kg/day PO × 21 days Diethylcarbamazine 300 mg/week for prophylaxsis |
Microfilariacidal only |
Mansonella ozzardi | Ivermectin 200 mcg/kg PO × 1 | Lactating/pregnant women Weight > 15 kg |
Mansonella perstans | Mebendazole 100 mg PO bid × 30 days Albendazole 400 mg PO bid × 10 days |
Often not effective |
Mansonella streptocerca | Diethylcarbamazine 6 mg/kg/day PO × 14-21 days Ivermectin 150 mcg/kg PO × 1 |
Lactating/pregnant women Weight > 15 kg |
Onchocerca | Ivermectin 150-200 mcg/kg PO × 1; can repeat in 3-6 mo | Microfilariacidal only Mazzotti reaction |
Doxycycline 100-200 mg PO once daily × 6 wk Mebendazole 1 g PO bid × 28 days |
Pulmonary eosinophilia | |
Flatworms: Cestoidea | ||
Taenia solium: intestinal | Praziquantel 10-20 mg/kg PO × 1 + Cimetidine |
Hepatic impairment, does not inactivate eggs released from dead adult worms |
Niclosamide 2 g PO | ||
Taenia solium: neurocysticercosis | Praziquantel 50-60 mg/kg/day PO × 15-30 days + steroids albendazole 15 mg/kg/day PO × 8-30 days If > 60 kg, then 400 mg PO bid × 8-30 days + Anticonvulsants and corticosteroids: Dexamethasone 16-24 mg/day PO Followed by prednisone 1 mg/kg/day PO Taper over 2-3 wk ± Endoscopic surgery/ventriculoperitoneal shunt |
Hepatic impairment Maximum, 800 mg/day |
Echinococcus | Nonsurgical cysts: albendazole 10-15 mg/kg/day or mebendazole 40-50 mg/kg/day for 3-6 months Surgical adjuncts: albendazole 15 mg/kg/day PO, start minimum of 4 days before procedure and continue for 8 weeks after procedure Intraoperative: praziquantel 40 mg/kg/day PO PAIR 90% ethanol or 20% hypertonic saline |
Neutropenia and liver toxicity with prolonged albendazole and mebendazole use |
Praziquantel 50 mg/kg/day PO × 2 wk | Hepatic impairment | |
Diphyllobothrium latum | Praziquantel 25 mg/kg PO × 1 | |
Diphyllobothrium other spp. | Praziquantel 10 mg/kg PO × 1 Niclosamide 2 g PO × 1 adults 1 g PO × 1 pediatrics >6 yr old |
|
Flukes: Trematoda | ||
Schistosoma | Praziquantel 40-60 mg/kg/day PO × 1 day | Age > 4 yr Hepatic impairment |
Other Flukes | ||
Clonorchis Fasciola Opisthorchis Paragonimus |
Praziquantel 75 mg/kg/day PO × 1-2 days Albendzole 10 mg/kg/day PO × 7 days |
Hepatic impairment |
Bedbugs: Cimex spp. | Antipuritics ± corticosteroids | |
Scabies: Sarcoptes spp. | Permethrin 5% topical, 8-14 hr; wash off ± repeat 1 wk | Age > 2 mo First-line treatment in United States Resistance reported |
Lindane 1% topical, 6 hr then wash; can repeat in 1 wk | Lactating/pregnant women Increased seizure risk Aplastic anemia risk Weight > 50 kg Age > 6 mo Resistance reported |
|
Crotamiton 10% topical bid × 5 days or × 1 for 48 hr total |
Lactating/pregnant women | |
Benzyl benzoate 10-25% 2-3 × in 1 day | Lactating/pregnant women Age > 2 yr Not available in United States Effective in permethrin-resistant scabies |
|
Sulfur 2-10% petroleum, 2-3 days | Dermatitis Stains clothing Not available in United States |
|
Sulfur 10% may be more effective than permethrin for crusted scabies23 | ||
Malathion 0.5% 8-12 hr | Lactating/pregnant women Age > 6 mo Not available in United States |
|
Ivermectin 0.8% topical | Lactating/pregnant women Weight > 15 kg |
|
Ivermectin 200 mcg/kg PO × 1; repeat in 2 wk or Ivermectin 250-350 mcg/kg PO × 1 |
||
Lice: Pediculus humanus capitis | Permethrin 1% topical 8-14 hr; wash off ± repeat 1 wk May use 5% topical if >2 mo old |
Resistance reported |
Lindane 1% topical, 6 hr then wash; can repeat in 1 wk | Lactating/pregnant women Increased seizure risk Aplastic anemia risk Weight > 50 kg Age > 6 mo Resistance reported |
|
Malathion 0.5% topical 12 hr | Age > 6 mo Flammable Ovicidal Resistance reported29 |
|
Carbaryl 0.5% topical | Carcinogenic26 Available in United Kingdom |
|
Benzyl alcohol 5%, topical 10 min; repeat in 10 days | Age > 6 mo Approved in United States30,31 |
|
Ivermectin 200-400 mcg/kg PO × 1; repeat in 7-10 days | Lactating/pregnant women Weight > 15 kg |
|
Ivermectin 200 mcg/kg PO days 1, 2, 10 | Good option in resource-poor area36,37 | |
Spinosad 0.9% cream 10 min; wash | Under development32 | |
Dimethicone 4% lotion | Used in United Kingdom, Europe, Brazil33,34 | |
Essential oils: lavender, coconut, citronella, anise, ylang-ylang | No investigative trials35 | |
Occlusive dressings: petroleum jellyMayonnaise, olive oil | Anecdotal home remedies | |
LouseBuster 30 min | Expensive Special training required No case-control trials27 |
bid, Twice daily; PAIR, percutaneous aspiration, infusion of scolicidal agents, and reaspiration; PO, orally; tid, three times daily.
Frankowski BL, Bocchini JA, Jr., Committee on School Health the Committee on Infectious Diseases. Head lice. Pediatrics. 2010;126:392–403.
Goddard J, DeShazo R. Bed bugs (Cimex lectularius) and clinical consequences of their bites. JAMA. 2009;301:1358–1366.
Hicks M, Elston DM. Scabies. Dermatol Ther. 2009;22:279–292.
Hotez PF, Brindley PJ, Bethony JM, et al. Helminth infections: the great neglected tropical diseases. J Clin Invest. 2008;118:1311–1321.
Jackson JA, Friberg IM, Little S, Bradley JE. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology. 2008;126:18–27.
1 Hotez PF, Brindley PJ, Bethony JM, et al. Helminth infections: the great neglected tropical diseases. J Clin Invest. 2008;118:1311–1321.
2 Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections. JAMA. 2008;299:1937–1948.
3 Loukas A, Constant SL, Bethony JM. Immunobiology of hookworm infection. FEMS Immunol Med Microbiol. 2005;42:115–124.
4 Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. 2007;41:1992–2001.
5 Boulware DR, Stauffer WM, Hendel-Paterson BR, et al. Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey. Am J Med. 2007;120:545–551.
6 Allen JE, Adjei O, Bain O, et al. Of mice, cattle, and humans: the immunology and treatment of river blindness. PLoS Negl Trop Dis. 2008;2:217–225.
7 Mahanty S, Garcia H. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol. 2010;91:172–184.
8 Jia WZ, Yan HB, Guo AJ, et al. Complete mitochondrial genomes of Taenia multiceps, T. hydatigena and T. pisiformis: additional molecular markers for a tapeworm genus of human and animal health significance. BMC Genomics. 2010;11:447–460.
9 Chow F, Garcia HH. Helminthic diseases: taeniasis and cysticercosis. In: Quah S, Heggenhougen K. International encyclopedia of public health. New York: Academic Press; 2008:361–368.
10 Garcia H, Del Brutto OH, Nash TE, et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg. 2005;72:3–9.
11 Zhang W, Roos AG, McManus DP. Mechanisms of immunity in hydatid disease: implications for vaccine development. J Immunol. 2008;181:6679–6685.
12 Scholz T, Garcia HH, Kuchta R, Wicht B. Update on the human broad tapeworm (genus Diphyllobothrium), including clinical relevance. Clin Microbiol Rev. 2009;22:146–160.
13 Mahmoud AAF. Schistosomiasis and other trematode infections. Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s principles of internal medicine, 17th ed, New York: McGraw-Hill, 2008.
14 Klaus JE. Can helminths of helminth-derived products be used in humans to prevent or treat diseases? Trends Immunol. 2009;30:75–82.
15 Jackson JA, Friberg IM, Little S, Bradley JE. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology. 2008;126:18–27.
16 Moreau E, Chauvin A. Immunity against helminths: interactions with the host and the intercurrent infections. J Biomed Biotechnol. 2010;2010:428593.
17 Smits HH, Everts B, Hartgers FC, Yazdanbakhsh M. Chronic helminth infections protect against allergic diseases by active regulatory process. Curr Allergy Asthma Rep. 2010;10:3–12.
18 Wang LJ, Cao Y, Shi HN. Helminth infections and intestinal inflammation. World J Gastroenterol. 2008;14:5125–5132.
19 Reinhardt K, Siva-Jothy M. Biology of the bed bugs (Cimicidae). Annu Rev Entomol. 2007;52:351–374.
20 Benoit J, Del Grosso NA, Yoder JA, Denlinger DL. Resistance to dehydration between bouts of blood feeding in the bed bug, Cimex lectularius, is enhanced by water conservation, aggregation, and quiescence. Am J Trop Med Hyg. 2007;76:987–993.
21 Goddard J, DeShazo R. Bed bugs (Cimex lectularius) and clinical consequences of their bites. JAMA. 2009;301:1358–1366.
22 Romero A, Potter MF, Potter DA, Haynes KF. Insecticide resistance in the bed bug: a factor in the pest’s sudden resurgence? J Med Entomol. 2007;44:175–178.
23 Hicks M, Elston DM. Scabies. Dermatol Ther. 2009;22:279–292.
24 Walton SF. The immunology of susceptibility and resistance to scabies. Parasite Immunol. 2010;32:532–540.
25 Hay RJ. Scabies and pyodermas: diagnosis and treatment. Dermatol Ther. 2009;22:466–474.
26 Nutanson I, Steen CJ, Schwartz RA, Janniger CK. Pediculus humanus capitis: an update. Acta Dermatoveneron Alp Panonica Adriat. 2008;17:147–154. 156-157, 159
27 Frankowski BL, Bocchini JA, Jr. Committee on School Health the Committee on Infectious Diseases. Head lice. Pediatrics. 2010;126:392–403.
28 Chosidow O, Giraudeau B, Cottrell J, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010;362:896–905.
29 Heymann WR. Head lice treatments: searching for the path of least resistance. J Am Acad Dermatol. 2009;61:323–324.
30 Hussar DA. New drugs: tapentadol hydrochloride, tolvaptan, and benzyl alcohol. J Am Pharm Assoc. 2009;49:704–708. (2003)
31 Meinking TL, Villar ME, Vicaria M, et al. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol. 2010;27:19–24.
32 Stough D, Shellabarger D, Quiring J, Gabrielsen AA, Jr. Efficacy and safety of spinosad and permethrin creme rinses for pediculosis capitis (head lice). Pediatrics. 2009;124:389–395.
33 Kurt O, Balcioglu IC, Burgess IF, et al. Treatment of head lice with dimethicone 4% lotion: comparison of two formulations in a randomized controlled trial in rural Turkey. BMC Public Health. 2009;9:441–450.
34 Heukelbach J, Pilger D, Oliveira FA, et al. A highly efficacious pediculicide based on dimethicone: randomized observer blinded comparative trial. BMC Infect Dis. 2008;8:115–125.
35 Burgess IF. Current treatments for pediculosis capitis. Curr Opin Infect Dis. 2009;22:131–136.
36 Munirathinam A, Sunish IP, Rajendran R, Tyagi BK. Impact of ivermectin drug combinations on Pediculus humanus capitis infestation in primary schoolchildren of south Indian rural villages. Int J Dermatol. 2009;48:1201–1205.
37 Pilger D, Heukelbach J, Khakban A, et al. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull World Health Organ. 2010;88:90–96.